Fourteen studies included only patients diagnosed with cytogenetically normal AML (CN‐AML), with the range in prevalence of FLT3‐ITD mutations in these patients being 7.3%–41.4% [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24]. Here, FLT3 is linked to acute myeloid leukemia.